Antibodies in Lupus

Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer
Antimitochondrial (AMA)
Anti-CD20 monoclonal (mAb)
Antiphospholipid (aPL)
Angiotensin II (ATIR)
C Reactive Protein (CRP)
Scl-70 (topo-I) (ATA)


There are a wide variety of autoantibodies associated with lupus. Some of the antibodies are helpful in diagnosing the illness, while others are more useful in detecting disease activity or potential complications. (Also see Autoimmune Diseases and Overview of Lupus)

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus (SLE). The data suggest that targeting plasmacytoid DCs may be beneficial for patients with SLE, especially those with cutaneous manifestations. PubMed, J Clin Invest, 2019 Mar 1;129(3):1359-1371.

Anti–CII Antibodies

Anti–CII antibody as a novel indicator to assess disease activity in systemic lupus erythematosus (SLE). Anti–dsDNA Abs and complement factors have been used as indicators of lupus activity and therefore, anti–CII Ab could be a novel indicator for monitoring activity of SLE. PubMed, Lupus.

Antimitochondrial (AMA)

Prevalence of antimitochondrial antibodies in subacute cutaneous lupus erythematosus (SCLE). A high prevalence of AMA-M2 was found in patients with SCLE. PubMed, Int J Dermatol, 10/05/2020.

Anti-CD20 monoclonal (mAb)

Anti-CD20 monoclonal antibodies (mAb) in Systemic Lupus Erythematosus. In this review, we will focus on B cell abnormalities and the rationale behind B-cell depletion therapy with anti-CD20 mAb. PubMed, Biologicals, 2020 Dec 4;S1045-1056(20)30136-6. (Also see Biologic Agents)

Antiphospholipid Antibodies (aPL)

Profiling of non-criteria antiphospholipid antibodies in patients with systemic lupus erythematosus (SLE): differentiation of thrombotic SLE patients and risk of recurrence of thrombosis. Profiling of antiphospholipid antibodies by line immunoassay can differentiate SLE patients with thrombosis from SLE patients without thrombosis. PubMed, Lupus, 2020 Mar 4:961203320909952. (Also see Symptoms and Complications of Lupus)

Progression of subclinical atherosclerosis in systemic lupus erythematosus (SLE) versus rheumatoid arthritis: the impact of low disease activity. Plaque progression is accelerated in SLE regardless of disease activity, and is associated with antiphospholipid antibodies and the Systemic Coronary Risk Evaluation. PubMed, Rheumatology (Oxford), 08/08/2018.

Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus. Presence of antiphospholipid syndrome or persistent antiphospholipid antibodies may be related to non–thrombotic and non–gestational systemic lupus erythematosus manifestations. PubMed, Lupus, 2018 Apr;27(4):665-669.

Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus (SLE). In this SLE cohort, the non–criteria aPL aD1 IgG and aPS-PT IgG performed differently. PubMed, Rheumatology (Oxford), 04/17/2018.

Antiphospholipid antibodies in patients with upper-extremity deep vein thrombosis (UEDVT). UEDVT could be the first clinical symptom of Antiphospholipid syndrome, and may be the first clinical manifestation of preceding the development of Systemic Lupus Erythematosus by several years. PubMed, Cent Eur J Immunol. (Also see Antiphospholipid Syndrome)

Angiotensin II (ATIR)

Angiotensin II receptor agonist antibodies (AT1R-AAs) are associated with microvascular damage in lupus nephritis (LN). AT1R-AAs are prevalent in active LN patients and are associated with histologic features of microvascular damage. PubMed, Lupus, 2020 Feb 10:961203320904787.

C Reactive Protein (Anti-CRP)

Anti-CRP antibodies in systemic lupus erythematosus. Anti-CRP autoantibodies, which are found in 35 to 40% of SLE patients, increase the cardiovascular risk by interacting with the monomeric (degraded) form of CRP. PubMed, Joint Bone Spine.

NKG2A Antibodies

Functional anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies in patients with systemic lupus erythematosus (SLE). Anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies have the capacity to deplete certain NK cell subsets and interfere with particular NK cell function and may promote the pathogenesis of SLE. PubMed, Arthritis Rheumatol.

Scl-70 (topo-I)(ATA)

Topoisomerase I (topo-1) in Human Disease Pathogenesis and Treatments. In this review, we will summarize our current understandings on how TOP1 contributes to human diseases and how its activity is targeted for disease treatments. PubMed, Genomics Proteomics Bioinformatics.

SM (Anti-SM antibodies)

Hashimoto thyroiditis (HT), anti–thyroid antibodies and systemic lupus erythematosus (SLE). There is a two–fold increased risk of HT in SLE patients, Anti–SM antibodies favor this association and also double antibody positivity. PubMed, Int J Rheum Dis.

Go to Treatments for Lupus

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.